Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
NCT00683670
Completed
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Melanoma
Register for Updates
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
NCT03241940
Active Not Recruiting
This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. These proteins are c... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
06/25/2025
Locations: Lucile Packard Children's Hospital Stanford University, Palo Alto, California
Conditions: B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Register for Updates
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
NCT06829199
Withdrawn
Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC). The goals of this study are to learn about the safety of boserolimab given with standard treatment before surgery and to learn if people tolerate it and how many people have no signs of cancer in the tissues and lymph nodes removed during surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Optum Care Cancer Center ( Site 0004), Las Vegas, Nevada +1 locations
Conditions: Early Triple Negative Breast Cancer
Register for Updates
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT06609928
Recruiting
This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 chimeric antigen receptor (CAR) T cells in treating pediatric patients with FOLR1+ acute myeloid leukemia (AML) that has come back after a period of improvement (recurrent) or has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a pa... Read More
Gender:
ALL
Ages:
6 years and below
Trial Updated:
06/25/2025
Locations: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Conditions: Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
Register for Updates
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
NCT01275677
Completed
This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies,... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +1282 locations
Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Register for Updates
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
NCT04884035
Recruiting
This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Mayo Clinic - Arizona, Scottsdale, Arizona +33 locations
Conditions: Lymphoma, B-Cell
Register for Updates
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
NCT00869232
Active Not Recruiting
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to individuals treated with standard chemotherapy. Past studies conducted at the MIRT and at other institutions have shown that participants with high-risk features by gene array studies tend to have shorte... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/25/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
NCT00734877
Active Not Recruiting
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3). Note: Randomization has been discontinued and accrual is closed to the L-TT3 arm. This trial is currently enrolling as a single-arm trial for patients to receive S-TT3.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/25/2025
Locations: University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
NCT06364423
Recruiting
Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of these cancer cells. Researchers can modify a person's own immune cells (T cells) to target CD19. When these modified T cells are returned to the body-a treatment called anti-CD19 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: B-Cell Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic
Register for Updates
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
NCT03573700
Active Not Recruiting
SJCAR19 is a research study seeking to evaluate the use of chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of pediatric, adolescent and young adult patients with relapsed or refractory CD19+ acute lymphoblastic leukemia (ALL). CAR therapy combines two of the body's basic disease fighters: antibodies and T Cells. For this type of therapy, peripheral (circulating) immune cells are collected and then undergo a manufacturing process to engineer them to m... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
06/25/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Register for Updates
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
NCT04789408
Terminated
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Stanford Cancer Center, Stanford, California +8 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03150693
Suspended
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
06/24/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +457 locations
Conditions: B Acute Lymphoblastic Leukemia
Register for Updates